Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Calum A MacRae. (2010) Cardiac arrhythmia: in vivo screening in the zebrafish to overcome complexity in drug discovery. Expert Opinion on Drug Discovery 5:7, pages 619-632.
Read now
Read now
Phillip J Stansfeld, Michael J Sutcliffe & John S Mitcheson. (2006) Molecular mechanisms for drug interactions with hERG that cause long QT syndrome. Expert Opinion on Drug Metabolism & Toxicology 2:1, pages 81-94.
Read now
Read now
Articles from other publishers (56)
Taeho Kim, Kee-Choo Chung & Hwangseo Park. (2023) Derivation of Highly Predictive 3D-QSAR Models for hERG Channel Blockers Based on the Quantum Artificial Neural Network Algorithm. Pharmaceuticals 16:11, pages 1509.
Crossref
Crossref
Aziza El Harchi & Jules C. Hancox. (2023) hERG agonists pose challenges to web-based machine learning methods for prediction of drug-hERG channel interaction. Journal of Pharmacological and Toxicological Methods 123, pages 107293.
Crossref
Crossref
Hongsong Feng & Guo-Wei Wei. (2023) Virtual screening of DrugBank database for hERG blockers using topological Laplacian-assisted AI models. Computers in Biology and Medicine 153, pages 106491.
Crossref
Crossref
Mengyi Shan, Chen Jiang, Lu‐Ping Qin & Gang Cheng. (2022) A Review of Computational Methods in Predicting hERG Channel Blockers. ChemistrySelect 7:31.
Crossref
Crossref
Hamideh P Fallah, Ekta Ahuja, Haoquan Lin, Jinlong Qi, Qian He, Shan Gao, Hailong An, Jian Zhang, Yongzhen Xie & Dong Liang. (2022) A Review on the Role of TRP Channels and Their Potential as Drug Targets_An Insight Into the TRP Channel Drug Discovery Methodologies. Frontiers in Pharmacology 13.
Crossref
Crossref
Xudong Zhang, Jun Mao, Min Wei, Yifei Qi & John Z. H. Zhang. (2022) HergSPred: Accurate Classification of hERG Blockers/Nonblockers with Machine-Learning Models. Journal of Chemical Information and Modeling 62:8, pages 1830-1839.
Crossref
Crossref
Jinghua Zhao & Menghang Xia. 2022. High-Throughput Screening Assays in Toxicology. High-Throughput Screening Assays in Toxicology
21
28
.
Nataraj Sekhar Pagadala. (2021) Computational prediction of hERG blockers using homology modelling, molecular docking and QuaSAR studies. Results in Chemistry 3, pages 100101.
Crossref
Crossref
Leela Sarath Kumar Konda, S. Keerthi Praba & Rajendra Kristam. (2019) hERG liability classification models using machine learning techniques. Computational Toxicology 12, pages 100089.
Crossref
Crossref
Reka A. Otvos, Kristina B.M. Still, Govert W. Somsen, August B. Smit & Jeroen Kool. (2019) Drug Discovery on Natural Products: From Ion Channels to nAChRs, from Nature to Libraries, from Analytics to Assays. SLAS Discovery 24:3, pages 362-385.
Crossref
Crossref
Xiao Li, Yuan Zhang, Huanhuan Li & Yong Zhao. (2017) Modeling of the hERG K+ Channel Blockage Using Online Chemical Database and Modeling Environment (OCHEM). Molecular Informatics 36:12, pages 1700074.
Crossref
Crossref
Paul A. Lapchak & John H. Zhang. (2016) The High Cost of Stroke and Stroke Cytoprotection Research. Translational Stroke Research 8:4, pages 307-317.
Crossref
Crossref
Paul A. Lapchak & Paul D. Boitano. 2017. Neuroprotective Therapy for Stroke and Ischemic Disease. Neuroprotective Therapy for Stroke and Ischemic Disease
3
71
.
Hai-bo Yu, Bei-yan Zou, Xiao-liang Wang & Min Li. (2016) Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay. Acta Pharmacologica Sinica 37:1, pages 111-123.
Crossref
Crossref
Li Di & Edward H. Kerns. 2016. Drug-Like Properties. Drug-Like Properties
423
432
.
Claire Townsend & Barry S. Brown. (2013) Predicting Drug‐Induced QT Prolongation and Torsades de Pointes: A Review of Preclinical Endpoint Measures. Current Protocols in Pharmacology 61:1.
Crossref
Crossref
Shiva A. Portonovo, Carl S. Salazar & Jacob J. Schmidt. (2012) hERG drug response measured in droplet bilayers. Biomedical Microdevices 15:2, pages 255-259.
Crossref
Crossref
A Wickenden, B Priest & G Erdemli. (2012) Ion channel drug discovery: challenges and future directions. Future Medicinal Chemistry 4:5, pages 661-679.
Crossref
Crossref
Paweł Szymański, Magdalena Markowicz & Elżbieta Mikiciuk-Olasik. (2011) Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests. International Journal of Molecular Sciences 13:1, pages 427-452.
Crossref
Crossref
Xiaojing Su, Edmond W.K. Young, Heather A.S. Underkofler, Timothy J. Kamp, Craig T. January & David J. Beebe. (2011) Microfluidic Cell Culture and Its Application in High-Throughput Drug Screening: Cardiotoxicity Assay for hERG Channels. SLAS Discovery 16:1, pages 101-111.
Crossref
Crossref
Ingemar Jacobson, Leif Carlsson & Göran Duker. (2011) Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit. Journal of Pharmacological and Toxicological Methods 63:1, pages 40-46.
Crossref
Crossref
Xi-Ping HuangThomas ManganoSandy HufeisenVincent SetolaBryan L. Roth. (2010)
Identification of Human
Ether-à-go-go
Related Gene Modulators by Three Screening Platforms in an Academic Drug-Discovery Setting
. ASSAY and Drug Development Technologies 8:6, pages 727-742.
Crossref
Crossref
Terry R. BridalMichael MargulisXin WangMichael DonioSteve Sorota. (2010)
Comparison of Human
Ether-à-go-go
Related Gene Screening Assays Based on IonWorks Quattro and Thallium Flux
. ASSAY and Drug Development Technologies 8:6, pages 755-765.
Crossref
Crossref
Munikumar R. Doddareddy, Elisabeth C. Klaasse, Shagufta, Adriaan P. IJzerman & Andreas Bender. (2010) Prospective Validation of a Comprehensive In silico hERG Model and its Applications to Commercial Compound and Drug Databases. ChemMedChem 5:5, pages 716-729.
Crossref
Crossref
Vito G. Sasseville, William R. Foster & Bruce D. Car. 2009. Evaluation of Drug Candidates for Preclinical Development. Evaluation of Drug Candidates for Preclinical Development
219
252
.
Khuram W. Chaudhary & Barry S. Brown. 2009. Evaluation of Drug Candidates for Preclinical Development. Evaluation of Drug Candidates for Preclinical Development
253
279
.
Steven A. Titus, Daniel Beacham, Sampada A. Shahane, Noel Southall, Menghang Xia, Ruili Huang, Elizabeth Hooten, Yong Zhao, Louie Shou, Christopher P. Austin & Wei Zheng. (2009) A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Analytical Biochemistry 394:1, pages 30-38.
Crossref
Crossref
Dimitri Mikhailov, Martin Traebert, Qiang Lu, Steven Whitebread & William Egan. 2009. Hit and Lead Profiling. Hit and Lead Profiling
387
413
.
Jerzy Karczewski, Jixin Wang, Stefanie A. Kane, Laszlo Kiss, Kenneth S. Koblan, J. Christopher Culberson & Robert H. Spencer. (2009) Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel. Biochemical Pharmacology 77:10, pages 1602-1611.
Crossref
Crossref
Sebastian Polak, Barbara Wiśniowska & Jerzy Brandys. (2008)
Collation, assessment and analysis of literature
in vitro
data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties
. Journal of Applied Toxicology 29:3, pages 183-206.
Crossref
Crossref
Sitarama B. Gunturi, Kotu Archana, Akash Khandelwal & Ramamurthi Narayanan. (2008) Prediction of hERG Potassium Channel Blockade Using kNN-QSAR and Local Lazy Regression Methods. QSAR & Combinatorial Science 27:11-12, pages 1305-1317.
Crossref
Crossref
Keith A. Houck & Robert J. Kavlock. (2008) Understanding mechanisms of toxicity: Insights from drug discovery research. Toxicology and Applied Pharmacology 227:2, pages 163-178.
Crossref
Crossref
Edward H. Kerns & Li Di. 2008. Drug-like Properties: Concepts, Structure Design and Methods. Drug-like Properties: Concepts, Structure Design and Methods
378
385
.
David J. Diller & Doug W. Hobbs. (2007) Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation. Journal of Computer-Aided Molecular Design 21:7, pages 379-393.
Crossref
Crossref
David H. Singleton, Helen Boyd, Jill V. Steidl-Nichols, Matt Deacon, Marcel J. de Groot, David Price, David O. Nettleton, Nora K. Wallace, Matthew D. Troutman, Christine Williams & James G. Boyd. (2007) Fluorescently Labeled Analogues of Dofetilide as High-Affinity Fluorescence Polarization Ligands for the Human Ether-a-go-go-Related Gene (hERG) Channel. Journal of Medicinal Chemistry 50:13, pages 2931-2941.
Crossref
Crossref
Matt Deacon, David Singleton, Nikki Szalkai, Rodger Pasieczny, Chris Peacock, David Price, James Boyd, Helen Boyd, Jill V. Steidl-Nichols & Christine Williams. (2007) Early evaluation of compound QT prolongation effects: A predictive 384-well fluorescence polarization binding assay for measuring hERG blockade. Journal of Pharmacological and Toxicological Methods 55:3, pages 255-264.
Crossref
Crossref
Mark D. McBriar, Henry Guzik, Sherry Shapiro, Ruo Xu, Jaroslava Paruchova, John W. Clader, Kim O’Neill, Brian Hawes, Steve Sorota, Michael Margulis, Kristal Tucker, Daniel J. Weston & Kathleen Cox. (2006) Bicyclo[3.1.0]hexyl urea melanin concentrating hormone (MCH) receptor-1 antagonists: Impacting hERG liability via aryl modifications. Bioorganic & Medicinal Chemistry Letters 16:16, pages 4262-4265.
Crossref
Crossref
Tim Hammond & Jean-Pierre Valentin. 2006. The Process of New Drug Discovery and Development, Second Edition. The Process of New Drug Discovery and Development, Second Edition
243
289
.
Han Choe, Kwang Hoon Nah, Soo Nam Lee, Han Sam Lee, Hui Sun Lee, Su Hyun Jo, Chae Hun Leem & Yeon Jin Jang. (2006) A novel hypothesis for the binding mode of HERG channel blockers. Biochemical and Biophysical Research Communications 344:1, pages 72-78.
Crossref
Crossref
Khuram W. ChaudharyJanet M. O'NealZun-Li MoBernard FerminiRobert H. GallavanAnthony Bahinski. (2006) Evaluation of the Rubidium Efflux Assay for Preclinical Identification of hERG Blockade. ASSAY and Drug Development Technologies 4:1, pages 73-82.
Crossref
Crossref
Brian D. Guth. 2006. Drug Discovery and Evaluation. Drug Discovery and Evaluation
61
94
.
Giovanni Cianchetta, Yi Li, Jiesheng Kang, David Rampe, Arnaldo Fravolini, Gabriele Cruciani & Roy J. Vaz. (2005) Predictive models for hERG potassium channel blockers. Bioorganic & Medicinal Chemistry Letters 15:15, pages 3637-3642.
Crossref
Crossref
Arnulf Dorn, Francis Hermann, Andreas Ebneth, Hendrick Bothmann, Gerhard Trube, Klaus Christensen & Christian Apfel. (2005) Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition. SLAS Discovery 10:4, pages 339-347.
Crossref
Crossref
Michael C. Sanguinetti & John S. Mitcheson. (2005) Predicting drug–hERG channel interactions that cause acquired long QT syndrome. Trends in Pharmacological Sciences 26:3, pages 119-124.
Crossref
Crossref
Steve SorotaXue-Song ZhangMichael MargulisKristal TuckerTony Priestley. (2005) Characterization of a hERG Screen Using the IonWorks HT: Comparison to a hERG Rubidium Efflux Screen. ASSAY and Drug Development Technologies 3:1, pages 47-57.
Crossref
Crossref
Haiyan Sun, Sojin Shikano, Qiaojie Xiong & Min Li. (2004) Function recovery after chemobleaching (FRAC): Evidence for activity silent membrane receptors on cell surface. Proceedings of the National Academy of Sciences 101:48, pages 16964-16969.
Crossref
Crossref
CHRISTINA DAVIE, JEAN PIERRE‐VALENTIN, CHRIS POLLARD, NICK STANDEN, JOHN MITCHESON, PAUL ALEXANDER & BOB THONG. (2004)
Comparative Pharmacology of Guinea Pig Cardiac Myocyte and Cloned hERG (I
Kr
) Channel
. Journal of Cardiovascular Electrophysiology 15:11, pages 1302-1309.
Crossref
Crossref
Gilbert J. Diaz, Katina Daniell, Sandra T. Leitza, Ruth L. Martin, Zhi Su, Jeffrey S. McDermott, Bryan F. Cox & Gary A. Gintant. (2004) The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. Journal of Pharmacological and Toxicological Methods 50:3, pages 187-199.
Crossref
Crossref
Saman Rezazadeh, J. Christian Hesketh & David Fedida. (2004) Rb+ Flux through hERG Channels Affects the Potency of Channel Blocking Drugs: Correlation with Data Obtained Using a High-Throughput Rb+ Efflux Assay. SLAS Discovery 9:7, pages 588-597.
Crossref
Crossref
Larisa StankovichDavid WicksSasko DespotovskiDong Liang. (2004) Atomic Absorption Spectroscopy in Ion Channel Screening. ASSAY and Drug Development Technologies 2:5, pages 569-574.
Crossref
Crossref
Keith Finlayson, Harry J. Witchel, James McCulloch & John Sharkey. (2004) Acquired QT interval prolongation and HERG: implications for drug discovery and development. European Journal of Pharmacology 500:1-3, pages 129-142.
Crossref
Crossref
Charles A. Blum, Xiaozhang Zheng & Stéphane De Lombaert. (2004)
Design, Synthesis, and Biological Evaluation of Substituted 2-Cyclohexyl-4-phenyl-1
H
-imidazoles: Potent and Selective Neuropeptide Y Y5-Receptor Antagonists
. Journal of Medicinal Chemistry 47:9, pages 2318-2325.
Crossref
Crossref
Paul B Bennett & Heather R.E Guthrie. (2003) Trends in ion channel drug discovery: advances in screening technologies. Trends in Biotechnology 21:12, pages 563-569.
Crossref
Crossref
Sikander Gill, Raj Gill, Soo Sen Lee, J. Christian Hesketh, David Fedida, Saman Rezazadeh, Larisa Stankovich & Dong Liang. (2003) Flux Assays in High Throughput Screening of Ion Channels in Drug Discovery. ASSAY and Drug Development Technologies 1:5, pages 709-717.
Crossref
Crossref
Clay W Scott, Deidre E Wilkins, Shephali Trivedi & Denis J Crankshaw. (2003) A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry. Analytical Biochemistry 319:2, pages 251-257.
Crossref
Crossref
J. Fraser Glickman. (2003) Literature Search and Review. ASSAY and Drug Development Technologies 1:supplement 2, pages 209-214.
Crossref
Crossref